Tag Archives: MRK stock research
Merck & Co (MRK) 25Q3 Update
25Q3 sales rose 3.7% to $17.3 billion, exceeding my estimate by 3.9%. The revenue beat was due mostly to higher than anticipated sales of GARDASIL. Although GARDASIL sales were down 24% YOY, they were up 55% sequentially, breaking a four … Continue reading
Merck & Co (MRK) 25Q2 Update
25Q2 sales decreased 1.9% to $15.8 billion and were 0.8% below my estimate. GARDASIL sales declined by $1.3 billion or 55%, hurt by a lack of pull through in China. (Thus, the company’s suspension of shipments to China will continue … Continue reading
Merck & Co (MRK) 25Q1 Update
25Q1 sales decreased 1.6% to $15.5 billion and were 2.0% below my estimate. Excluding currency, sales rose 1%. Sales gains in KEYTRUDA, WINREVAIR and Animal Health offset a 41% drop in GARDASIL sales, as a sharp drop in sales in … Continue reading
Merck & Co (MRK) 24Q4 Update
24Q4 sales rose 6.8% to $15.6 billion. Excluding currency, sales rose 9%. Once again, a high teens percentage gain in KEYTRUDA sales more than offset declining sales in most of the rest of the portfolio. GAAP diluted EPS was $1.48, … Continue reading